The expression standards that pharmaceutical materials must meet sit one level above the prohibition on stating falsehoods. A text composed entirely of facts can still leave the reader with a false impression — through the selection of which facts to include, where emphasis is placed, what is omitted, and how the page is laid out. This is why the decisions a writer makes are judged not only by "is what I wrote accurate?" but by "what will the reader take away?" The terms defined in this category are the vocabulary needed to answer that second question.
Two of the three foreword pillars — ① blocking misunderstanding and ② implementing balance on the printed page — cannot be applied without this vocabulary. Whether a statement is exaggerated is determined not by the truth value of its content but by the reasonableness of the impression it creates. Implementing balance on the page is a concrete obligation: if efficacy is addressed, safety must be presented at equal or greater prominence. Judgments about what may and may not be written in a features column — the section most prone to exaggeration — require an accurate grasp of these terms.
01Term reference — expression regulation vocabulary
| Term | Meaning | Notes and implications |
|---|---|---|
| Exaggerated expression | Any expression that gives the reader a false impression — of greater efficacy or safety than the evidence supports — even when every stated fact is accurate | Eliminating falsehoods does not eliminate exaggeration. The question is not "is this true?" but "is the impression this creates warranted?" |
| Misleading expression | Broader category encompassing any expression that, through context, placement, or omission, leads the reader to an unwarranted conclusion, even if each sentence is individually accurate | The accuracy of individual sentences and the accuracy of the overall impression conveyed are separate matters. The latter is what is being regulated |
| Disparagement / denigration | Statements that demean a competitor's product or company. Factual comparison is permissible; evaluative commentary asserting superiority or inferiority is not | Placing a competitor in an unfavorable light to elevate a company's own product is the mirror image of exaggerating that product's merits. Only facts from appropriately designed trials may be used |
| Emphasis on / guarantee of safety | Emphasis on safety to a degree that conflicts with the electronic package insert's warnings, contraindications, or adverse reactions; or any expression that gives the reader a sense of certainty that the product is safe | This prohibition does not ban discussing safety. It bans conveying a level of safety that exceeds what the evidence supports |
| Asymmetric obligation | The duty to disclose safety information even when it is unfavorable to the company. Favorable and unfavorable information are held to the same disclosure standard | "Having mentioned it" may not be enough. If unfavorable information appears in small type at the end of the document, or behind a click in an electronic material, it has not been effectively disclosed |
| Verifiability | The state in which the reader can trace a claim in a material back to the primary source by following the citation — author, journal, volume, issue, and date | The foreword's third pillar. No source, incomplete citation details, or URL alone are all insufficient. A peer-reviewed original article with full bibliographic information is the standard |
| Balance (page-level implementation) | The obligation, at the level of page design, to present safety information at equal or greater type size and visual prominence than efficacy information when both appear in the same material | "We mention safety" is insufficient. Type size, placement, and allocation of space must be proportionate |
| Features / characteristics column | The section of the product information summary that conveys the product's primary characteristics concisely. The section most prone to exaggeration and most vulnerable to infiltration by reference information or off-label content | Only confirmatory results from primary endpoints, grounded in the approved evidence, may appear here. Reference information, subgroup-limited results, and overseas-only data are excluded |
02Exaggerated expression — the requirement goes one step beyond prohibiting falsehood
What separates the prohibition on exaggeration from the prohibition on falsehood is the object of scrutiny. The prohibition on falsehood asks whether what was stated is true. The prohibition on exaggeration asks whether the impression the reader forms is warranted. An efficacy rate of 83% can be an accurate number and still create an exaggerated impression if the material conceals which population it came from, which endpoint it measured, and how the study was designed. No falsehood is needed to plant a misleading belief.
Four recurring types
Exaggerated expressions recur in recognizable patterns: ① emphasis on or guarantee of safety (claims that conflict with the package insert's warnings), ② authority-based impression management (materials centered on portraits of healthcare professionals), ③ bridging non-clinical evidence to clinical claims (connecting animal or in vitro results to clinical efficacy), and ④ generalizing from exceptional data (presenting unplanned subgroup analyses or secondary endpoint results as if they described the full trial population). None of these requires a stated falsehood; all of them exploit the gap between what was said and what the reader concludes.
Asking "is what I wrote accurate?" is a necessary but insufficient check. The writer must simultaneously ask "what will the reader's head contain after reading this?" The same true fact, presented in a different order, with different emphasis, in a different context of omission, can produce a different impression. The Guide regulates the presentation, not only the content.
03Disparagement — the line between factual comparison and evaluative commentary
A comparison with a competitor's product may be made by presenting facts from an appropriately designed trial. Stating that "in trial A, the company's product showed an improvement of X on the primary endpoint" is permissible. Stating that "the competitor's product has unacceptable tolerability" or "patients who failed on the other agent responded to this one" is evaluative commentary and constitutes disparagement.
The distinction matters because disparaging a competitor and exaggerating a company's own product frequently arise from the same passage. Placing a competitor in an unfavorable light produces the same effect as stating that the company's product is superior to what the evidence warrants. Eliminating evaluative commentary about competitors is part of what the foreword pillar of "blocking misunderstanding" requires.
04Asymmetric obligation — disclosing unfavorable information is not optional
The obligation on the material's author is to apply the same disclosure standard to favorable and unfavorable information alike. Safety information that reflects unfavorably on the company — adverse reaction frequencies, the content of warnings, precautions relevant to specific patient populations — must be disclosed.
But disclosure is not satisfied by mere inclusion. If unfavorable information appears in small type at the bottom of the page, or in an electronic material behind a click that the reader may never perform, it has not been effectively disclosed. The page-level implementation of balance is the design requirement that ensures effective disclosure — the same obligation expressed in the language of page architecture.
Relationship to the prohibition on safety emphasis and guarantees
The requirement to disclose unfavorable information and the prohibition on emphasizing or guaranteeing safety are two sides of the same principle. An author who is obligated to disclose a warning on the same page where a safety guarantee is printed places the reader in the position of receiving contradictory information. The Guide's repeated prohibition on safety emphasis and guarantees reflects the fact that this contradiction arises most often in this exact context.
05Balance (page-level implementation) — equal visibility for efficacy and safety
Balance is not a conceptual aspiration; it is a design obligation. When efficacy information appears in a product information summary, safety information — the outline of warnings, precautions, and adverse reactions — must be presented at equal or greater type size.
The practical implication is precise. When an efficacy graph and a safety table appear on the same page, if the graph is large and the table is reduced to supplementary fine print, the reader's attention will concentrate on efficacy. Even without any intent to minimize safety, the cognitive result is that safety recedes. The page-level implementation of balance is a design-stage correction for this unintentional bias.
06The features column — where exaggeration is most tempting
The features column exists to communicate the product's primary characteristics concisely. It is also the section of any material where the pressure toward exaggeration is strongest. The word "features" carries the connotation of "what sets this apart" and "what is superior" — an invitation to select and amplify.
Only confirmatory primary results, grounded in the approved evidence, may appear in the features column. Reference information stays out. So do subgroup-limited results, results from indications not approved domestically, and exploratory analyses. The more compelling a result seems as a "feature," the more likely it is that the underlying data do not come from a confirmatory primary endpoint. A clear prohibition is necessary to resist that pressure, and the Guide places it here.
Writing "fewer adverse reactions" or "favorable safety profile" in the features column directly conflicts with the prohibition on safety emphasis and guarantees. The first step before any such phrase appears in the features column is to verify that it does not conflict with the electronic package insert's warnings and contraindications. Safety statements in the features column require especially careful scrutiny.
Expression regulation terms define what is permitted in the space that remains after falsehood has been excluded. The prohibition on exaggeration covers the full range of "true but misleading" techniques. The prohibition on disparagement separates factual comparison from evaluative commentary. The asymmetric obligation requires disclosure of unfavorable information. Balance as page-level implementation translates that obligation into the language of design. The features column rules erect a clear fence at the point of greatest temptation. Verifiability requires that citations be given in a form the reader can follow back to the primary source. These are not independent prohibitions but a set of requirements all derived from a single purpose: preserving the healthcare professional's ability to evaluate a product on the basis of evidence.